Member Info for Laura2022

Moving freely

Puma

Sorry to hear that, I bought at c.0.7p but didn't like the £3mln cash burn in just 2mths since placing

Yes Tom ,

Could be an excellent buying opportunity. on the face of it still fully priced-

not certain of their competitive position, asthma a surprisingly tricky condition to diagnose particularly in young children,

said to be the best test in the market, what is the competition, mainly FEV1,FVC? and limited penetration overseas especially USA and in primary care, their kit mainly used in secondary care?

Also

highly cash generative piling up cash all the time with huge tax breaks from brought forward losses from the previous incarnation, Circassia.

They raised £3.8mlm in Feb

But today

"As at close of business on 15 April 2025, Belluscura had a cash balance of $1.1 million and debt of $0.6m"

I'm selling, risks too high..

See RNS

With the increasing pressure from regulatory agencies around the world for drug developers to utilise such techniques, these publications evidence how well Physiomics is positioned to support its clients in this growing marke

Dr Peter Sargent, CEO, commented:

"We are pleased to announce yet another publication, written in partnership with one of our long-standing clients, Ankyra Therapeutics. This is our third publication within three months, not only reflecting the impact of our expertise and services on supporting successful drug development programmes, but also the variety of clients we work with.

"These publications reflect the growing utility and impact of mathematical modelling on drug development. With the increasing pressure from regulatory agencies around the world for drug developers to utilise such techniques, these publications evidence how well Physiomics is positioned to support its clients in this growing market"

Absolutely KingH

It's becoming increasingly difficult when every mud sling is proved by a snipe made by others to initiate as can be shown by the timeline of posts

BUT I will keep to the request made by yourself King H

Let's hope others can too

Best wishes

Great week so far

I've purchased 60,000 shares above 56p

This looks such an undervalued company

Np Tom

We see Weatherden playing an increasingly important role in the global biotechnology sector. Our input is rapidly scaling across all segments and we are excited to see this translate into tangible improvements in patient outcomes and value realisation for our clients.”

>200 companies

We have advised, worked with and supported dozens of funds and biotechs.

>500 million plus

Our input is benefitting patient populations worldwide.

>25 billion USD

Our repeat and long-term clients have realised significant value gains since we became involved in their programmes

15-Apr-25 Deutsche Buy - 90.00 Reiteration

15-Apr-25 Berenberg Bank Buy - 90.00 Reiterati

Trout

Couldn't care less as you've proven..again...your agenda

King H

Fits nicely with this too

For the last few years the FDA has been engaging with drug developers to reform how dose optimisation is approached for new cancer drugs. In August 2024 they finalised the eagerly-awaited guidance for industry “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases” [1]. As part of our collaboration, Weatherden and Physiomics have worked together to help you understand and put this framework into action. Although this guidance is currently focused on oncology products, the potential benefits of these recommendations are true across therapeutic areas. 

Trout

How can they RNS something on a Numab RNS that's not Numab!!

Think for a second

Great news KingH

Jungle

Looking good ( did u get any of my last one too ?..niox

Moving